#75 Strong Clinical Relevance
High-quality evidence with meaningful patient or clinical significance.
Clinicians need this evidence summary to counsel patients seeking cannabis for mental health conditions, as the review demonstrates insufficient research supporting efficacy for most psychiatric disorders despite widespread off-label use. This gap between patient demand and clinical evidence creates liability and safety risks, requiring practitioners to establish clear prescribing guidelines and educate patients about unproven benefits. For Australian clinicians specifically, this finding should inform therapeutic decision-making given the regulatory environment permitting access to cannabis products.
A recent evidence review by the Royal Australian College of General Practitioners found insufficient scientific support for cannabis use in treating most mental health disorders, despite THC products being prescribed second only to pain conditions in Australia. The review highlights a concerning disconnect between clinical prescribing patterns and available evidence, as mental health indications now represent a substantial proportion of cannabis authorizations without robust randomized controlled trials demonstrating efficacy. Current evidence suggests potential benefits may be limited to specific conditions like chemotherapy-induced nausea, with most psychiatric applications lacking adequate research foundation. This gap between practice and evidence is particularly problematic given that many patients seeking cannabis for anxiety, depression, and other mental health conditions may be exposed to THC’s known risks, including psychosis, cognitive impairment, and cannabis use disorder, without demonstrated therapeutic benefit. Clinicians should exercise caution when considering cannabis for mental health indications and counsel patients that evidence-based alternatives remain the standard of care for these conditions. For practitioners considering cannabis prescriptions, prioritizing indications with established evidence and discussing with patients the lack of research support for psychiatric applications represents a more defensible and safer clinical approach.
“What we’re seeing in my practice is patients coming in with cannabis already in hand for anxiety or depression, having self-diagnosed based on anecdotal reports, when the evidence simply doesn’t support efficacy for these conditions and can actually worsen psychiatric symptoms in vulnerable individuals. We need to have honest conversations about this gap between patient expectations and clinical evidence rather than defaulting to either cheerleading or dismissal.”
🧠 While cannabis use for mental health conditions has grown substantially in clinical practice, recent evidence reviews highlight a critical gap between patient demand and robust scientific support for most psychiatric indications. The Royal Australian College of General Practitioners’ assessment reflects a broader international consensus that evidence for efficacy in depression, anxiety, and other common mental health disorders remains limited or absent, with particular concern around THC-dominant products that may actually worsen certain conditions. Clinicians should be aware that patient expectations often exceed available evidence, partly driven by anecdotal reports and evolving legal status, yet prescribing without solid evidence risks harm from adverse effects, dependency, and delayed appropriate treatment. Important confounders include heterogeneous product composition, variable dosing practices, self-selection bias in observational studies, and difficulty separating symptom relief from placebo effects or self-medication patterns. In practice, clinicians should document the evidence limitation clearly in conversations with patients seeking cannabis for mental
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it: